X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients.
Lead Product(s): ONC201
Therapeutic Area: Oncology Product Name: ONC201
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Collaboration with BARDA for the development of TEMBEXA (brincidofovir) has provided the United States government with a second therapeutic option to ensure the federal government’s readiness for a potential smallpox emergency.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Tembexa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority
Deal Size: $374.5 million Upfront Cash: $238.0 million
Deal Type: Agreement August 29, 2022
Details:
Chimerix signed a contract agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolutions.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Tembexa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Public Health Agency of Canada
Deal Size: $25.3 million Upfront Cash: Undisclosed
Deal Type: Agreement June 24, 2022
Details:
Chimerix expects to promptly provide treatment courses of TEMBEXA (brincidofovir) equivalent to the total value of the procurement contract. Execution of this contract will be the responsibility of Chimerix.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Tembexa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emergent BioSolutions
Deal Size: $9.3 million Upfront Cash: Undisclosed
Deal Type: Agreement June 23, 2022
Details:
TEMBEXA (brincidofovir), is an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. TEMBEXA is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Tembexa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emergent BioSolutions
Deal Size: $325.0 million Upfront Cash: $225.0 million
Deal Type: Acquisition May 16, 2022
Details:
The primary endpoint of the study is survival without the need for mechanical ventilation through day 28. The first cohort enrolled 12 patients randomized 1:1. One patient on DSTAT was ventilated and recovered.
Lead Product(s): Dociparstat sodium
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: DSTAT
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2021
Details:
ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation.
Lead Product(s): ONC201
Therapeutic Area: Oncology Product Name: ONC201
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Oncoceutics Inc
Deal Size: $78.0 million Upfront Cash: $39.0 million
Deal Type: Acquisition January 08, 2021
Details:
Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection.
Lead Product(s): Brincidofovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
